Faculty Profiles - MATSUSHITA, Tadashi

Papers - MATSUSHITA, Tadashi

Division display 1 - 20 of about 231 ／ All the affair displays >>

Use of cyclophosphamide and total lymphoid irradiation combined with cyclosporine in bone marrow transplantation for transfused severe aplastic anemia. Reviewed

"K. Miyamura, S. Kojima, K. Takeyama, T. Matsushita, M. Fukuda, K. Horibe, S. Minami, Y. Morishima, K. Matsuyama and Y. Kodera"

Bone Marrow Transplantation Vol. 3 page： 457-461 1988

Comparison between bone marrow transplantation and immuno-suppressive therapy in treatment of patients younger than 20 years with severe aplastic anemia Reviewed

"Kojima, S., Fukuda, M., Horibe, K., Matsuyama, K., Takeyama, K., Matsushita, T., Miyamura, K., Kimura, Y., Minami, S. and Kodera, Y."

Acta. Haematol. Jpn. Vol. 51 ( 1 ) page： 28-35 1988

Allogeneic bone marrow transplantation for Burkitt's lymphoma (stage IV). Reviewed

"Miyamura, K., Takeyama, K., Matsushita, T., Kimura, M., Minami, S., Yoshida, J., Matsuyama, K., Kodera, Y., Yamauchi, T. and Hiraiwa, A., et al."

"Jpn. J. Clin. Hematol. 29, 149-55, 1988" Vol. 29 ( 2 ) page： 149-55 1988

Cyclosporine as prophylaxis for graft versus host disease in adults undergoing allogeneic bone marrow transplantation Reviewed

"Matsushita, T., Akatsuka, Y., Towatari, M., Takeyama, K., Miyamura, K., Sugihara, T., Minami, S., & Kodera, Y."

Jpn. J. Clin. Hematol. Vol. 30 ( 4 ) page： 429-436 1989

Effects of ceftriaxone on severe infectious complications in hematological disorders. Tohkai Research Group on Infections in Hematological Disorders Reviewed

"Mitomo, Y., Nitta, M., Kodama, H., Kobayashi, M., Ikeda, Y., Kodera, Y., Matsushita, T., Ohara, K., Kamiya, O. and Shirakawa, S., et al."

Jpn J Antibiot Vol. 42 ( 4 ) page： 938-47 1989

Language：English Publishing type：Research paper (scientific journal)

"Ceftriaxone (CTRX), a new long acting antibiotic in the 3rd generation cephem group, was administered intravenously once or twice a day in daily doses of 1-6 g for at least 3 days to 86 patients with severe infections complicating hematopoietic disorders. Underlying diseases were acute leukemia in 41 cases, chronic leukemia in 3 cases, malignant lymphoma in 19 cases, myeloma in 7 cases and others. Most patients (55 cases) suffered from sepsis or suspected sepsis. As for efficacy rates classified by underlying diseases, the treatment was effective in 61.0% of patients with acute leukemia. As for efficacy rates classified by infections, the treatment was effective in 60.0% of patients with sepsis. No side effects were noted except rash in 2 patients. Abnormal hepatic functions were recognized in 3 patients but were not attributed to the agent in any case. The results indicate that CTRX is a safe and useful antibiotic for the treatment of severe infections accompanied by hematopoietic disorders."

Prolonged thrombocytopenia after autologous bone marrow transplantation Reviewed

"Kojima, S., Fukuda, M., Horibe, K., Matsuyama, T., Takeyama, K., Matsushita, T., Miyamura, K., Sugihara, T., Minami, S., & Kodera, Y."

Jpn. J. Clin. Hematol. Vol. 30 ( 2 ) page： 175-80 1989

Language：English Publishing type：Research paper (scientific journal)

"Thirty two patients with hematologic malignancies and solid tumors were treated with intensive therapy and autologous bone marrow transplantation. In nine out of 32 patients, it took more than 50 days to achieve a sustained platelet count of 50,000/microliter or greater. Significant associations with poor platelet recovery were found for patient age, diseases, period of cryopreservation, the kinds of eradicative therapy and in vitro purging. But most of these factors overlapped each other in the same patients. No correlation was found between platelet recovery and number of cells or CFU-GM infused."

Severe aplastic anemia remarkably improved by a treatment with antilymphocyte globulin, high-dose methylprednisolone and danazol Reviewed

Miyamura, K., Kojima, S., Takeyama, K., Matsushita, T., Minami, S., & Kodera, Y.

Jpn. J. Clin. Hematol. Vol. 30 ( 1 ) page： 72-77 1989

Language：English Publishing type：Research paper (scientific journal)

Sixteen-years-old female with severe aplastic anemia received a therapy combined with antilymphocyte globulin (ALG), high-dose methylprednisolone (m-PSL) and danazol. At the hospitalization, hematological examination demonstrated as follows; reticulocyte 21,000/microliters, granulocyte 350/microliters, platelet 10,000/microliters and hypocellular bone marrow. Treatment schedule were 1) m-PSL 1,000 mg (day 1-4), 500 mg (5-8)--then tapered. 2) ALG lg/day (day 4-8) 3) danazol 600 mg/day. During ALG administration, leukocytopenia and thrombocytopenia appeared but thereafter hematological recovery was obtained and the patient was free from supportive care. She developed mild diabetes mellitus and moderate liver dysfunction, nevertheless, both of which were controlled. At 3 months after the beginning of the treatment, hematological examination demonstrated as follows; reticulocyte 236,000/microliters, granulocyte 1,900/microliters, platelet 56,000/microliters and normocellular bone marrow. Although this immunosuppressive therapy was remarkably effective to this patient, immunological relation to the onset of aplastic anemia was not demonstrated in in vitro examination. This combined therapy seems to be effective one for patients with severe aplastic anemia.

The analysis of mutant factor IX gene responsible for the development of inhibitor in hemophilia B. Reviewed

"Matsushita, T."

Hematology & Oncology Vol. 21 ( 4 ) page： 472-477 1990

Gene diagnosis of hereditary bloodcoagulation factor disorders Reviewed

"Matsushita, T., Sugiura, I."

Jpn. J. Clin. Pathol. Vol. 85 page： 114-122 1990

Molecular diagnosis of inherited coagulation disorders--sequence analysis of hemophilia B patients with anti-factor IX antibodies Reviewed

"Tanimoto, M., Matsushita, T., Takamatsu, J. and Saito, H."

"J. Clin. Pathol. 38, 1041-1046, 1990" Vol. 38 ( 9 ) page： 1041-1046 1990

Language：English Publishing type：Research paper (scientific journal)

Seven hemophilia B patients with anti-factor IX antibodies are studied with molecular means. A total factor IX gene deletion was detected in four patients from three distinct families. Three other patients without detectable gene arrangements were investigated at the DNA sequence level. Enzymatic amplification of the factor IX gene and subsequent DNA sequencing revealed four novel nucleotide mutations in these patients. Patient HB 5 had two point mutations in his factor IX gene. One is located at nucleotide -793 from the translation start (G-A) and the other (C-T) was found in the codon for 191-Gln changing to a termination codon. Patient HB6 had a point mutation (G-A) in the splicing junction of intron g. A2 bp nucleotide deletion was detected in the third exon of the patient HB7 yielding 8 frameshifted amino acids and a stop codon. These results suggested that not only a large deletion of the factor IX gene but also point mutations or small deletion of the gene which may cause the substantial loss of the coding information for the mature protein are involved in the development of anti-factor IX antibodies in hemophilia B patients.

DNA sequence analysis of three inhibitor-positive hemophilia B patients without gross gene deletion. Identification of four novel mutations in factor IX gene. Reviewed

"Matsushita, T., Tanimoto, M., Yamamoto, K., Sugiura, I., Hamaguchi, M., Takamatsu, J., Kamiya, T. and Saito, H."

J Lab Clin Med. Vol. 116 page： 492-497 1990

Cytomegalovirus-induced gastritis in a bone marrow transplant patient. Reviewed

"Minami, H., Matsushita, T., Sugihara, T., Kodera, Y., Sakai, S. and Shimokata, K."

INTERNAL MEDICINE Vol. 29 page： 433-435 1990

Molecular genetics of hemophiliacs Reviewed

"Matsushita, T. and Saito, H."

Hematology & Oncology Vol. 22 ( 1 ) page： 129-140 1991

Homozygous protein C deficiency: identification of a novel missense mutation that causes impaired secretion of the mutant protein C. Reviewed

"Yamamoto, K., Matsushita, T., Sugiura, I., Takamatsu, J., Iwasaki, E., Wada, H., Deguchi, K., Shirakawa, S. and Saito, H."

J. Lab. Clin. Med. Vol. 119 page： 682-689 1991

"Three distinct point mutations in the factor IX gene of three CRM+ hemophilia B patients (Factor IX BMNagoya 2, B+ Nagoya 3 and 4)." Reviewed

"Hamaguchi, M., Tanimoto, M., Matsushita, T., Yamamoto, K., Sugiura, I., Takamatsu, J., Ogata, T., Kamiya, T. and H., S."

Thromb. Haemost. Vol. 65 page： 514-520 1991

Genotype establishments for protein C deficiency by use of a DNA polymorphism in the gene. Reviewed

"Yamamoto, K., Tanimoto, M., Matsushita, T., Kagami, K., Sugiura, I., Hamaguchi, M., Takamatsu, J. and Saito, H."

Blood Vol. 77 page： 2633-2636 1991

Direct carrier detection in hemophilia B kindreds: Use of modified primers (mutagenic primers) for enzymatic amplification of the factor IX gene. Reviewed

"Matsushita, T., Tanimoto, M., Yamamoto, K., Sugiura, I., Takamatsu, J., Kamiya, T. and Saito, H."

Thromb. Res. Vol. 63 page： 355-361 1991

A female hemophilia A combined with hereditary coagulation factor XII deficiency: a case report. Reviewed

"Matsushita, T., Takamatsu, J., Kagami, K., Takahashi, I., Sugiura, I., Hamaguchi, M., Kamiya, T. and Saito, H."

Am. J. Hematol Vol. 39 page： 137-141 1991

Mammalian expression systems of human blood coagulation factors. Reviewed

"Matsushita, T. and Emi, N."

Jpn. J. Thromb. Hemost. page： 546-549 1991

Elevation of factor VII activity and mass in coronary artery disease of varying severity Reviewed

"Suzuki, T., Yamauchi, K., Matsushita, T., Furumachi, T., Furui, H., Tsuzuki, J. and Saito, H."

Clin. Cardiol. Vol. 14 page： 731-736 1991

　 PREV - NEXT 　

<MATSUSHITA, Tadashi>

Papers - MATSUSHITA, Tadashi